2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1630

Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis
Abstract Number: 1704

Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Abstract Number: 870

Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, 2015
Abstract Number: 3252

Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis
Abstract Number: 2448

Contraceptive Methods in Women with Rheumatoid Arthritis
Abstract Number: 1334

Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients
Abstract Number: 518

Contribution of Patient Global Assessment on Loss and Gain of Disease Remission in Patients with Established Rheumatoid Arthritis in Clinical Practice
Abstract Number: 477

Conventional Non-Steroidal Anti-Inflammatory Drugs, but Not COX2 Selective Inhibitors, Are Beneficial on Vascular Function in Arthritis: A Study in Adjuvant Induced Arthritis
Abstract Number: 2598

Conversion Rate of Tuberculosis Screening Tests in Patients with Rheumatic Diseases While Receiving Anti-Tumor Necrosis Factor Alpha (anti-TNFα) Agents
Abstract Number: 1478

Coronary Artery Calcification in Rheumatoid Arthritis Patients Is Not Characterized By an Increase in Genes Associated with Coronary Artery Disease in the General Population
Abstract Number: 3191

Coronary Revascularization Procedure Rates and Risks Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort
Abstract Number: 1469

Coronary Territories Are Not Affected in Mexican Mestizo Patients with Rheumatoid Arthritis in Comparison to Matched Controls: Evaluation Using Speckle Tracking Echocardiography
Abstract Number: 1548

Correlates of Fatigue in People Living with Rheumatoid Arthritis
Abstract Number: 2810

Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
Abstract Number: 2485

Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].